Cas:921620-32-8 5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile manufacturer & supplier

Chemical Name:5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile

CAS.NO:921620-32-8

Synonyms:5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile

Molecular Formula:C₁₇H₈ClF₃N₄O

Molecular Weight:376.72000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:71.69000

Exact Mass:376.03400

LogP:4.87478

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile Use and application,5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile technical grade,usp/ep/jp grade.

Related News: Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,�� Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement. 5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile manufacturer Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations. 5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile supplier It is frequently associated with the presence of blasts or leukemic cells in the marrow. 5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile vendor J&J, in a statement, confirmed that the FDA authorized the two batches, but did not acknowledge the doses regulators decided should be tossed. 5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile factory Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,�� Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.